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ardiac Protection During Acute
yocardial Infarction: Where Do We Stand in 2004?
obert A. Kloner, MD, PHD, FACC,* Shereif H. Rezkalla, MD, FACC†
os Angeles, California; and Marshfield, Wisconsin
Despite better outcomes with early coronary artery reperfusion for the treatment of acute
ST-elevation myocardial infarction (MI), morbidity and mortality from acute myocardial
infarction (AMI) remain significant, the incidence of congestive heart failure continues to
increase, and there is a need to provide better cardioprotection (therapy that reduces the
amount of necrosis that may be coupled with better clinical outcome) in the setting of AMI.
Since the introduction of the concept of cardiac protection over a quarter of a century ago,
various interventions have been investigated to reduce myocardial infarct size. Intravenous
beta-blockers administered in the early hours of infarction were clearly shown to be of benefit.
Intravenous adenosine appeared promising for anterior wall AMIs, as did cariporide in some
studies. Glucose-insulin-potassium infusion was beneficial in certain subgroups of patients,
particularly diabetics. A variety of other medications were studied with negative or marginal
results. The best strategy to limit infarct size is early reperfusion with percutaneous coronary
stenting or thrombolytic therapy. Stenting is superior and should be adopted whenever there
is a qualified laboratory available. Available resources should focus on decreasing time from
onset of symptoms to start of reperfusion and maintaining vessel patency. Future studies
powered to better assess clinical outcome are needed for adjunctive therapy with adenosine,
KATP channel openers, Na
/H exchange inhibitors, and hypothermia. (J Am Coll
Cardiol 2004;44:276–86) © 2004 by the American College of Cardiology FoundationE
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eISTORY
arly after the description of acute myocardial infarction
AMI) in the beginning of the 20th century, its treatment
as quite limited. The main focus was on complete bed rest
nd dealing with the complications when they arose. It was
ot until the late 1960s to early 1970s that a new concept
urfaced—the concept that the extent of necrosis could be
imited by pharmacologic therapy. This concept of damage
ontrol was suggested by Braunwald in 1974 when he wrote,
I believe that we now stand at the threshold of a new era in
he treatment of AMI . . . it is now fair to accept the
osition that just because myocardial tissue lies within the
istribution of a recently occluded coronary artery does not
ean that it is necessarily condemned to death” (1).
In this review we will focus on which agents actually work
o limit necrosis in AMI in the clinical setting. The term
cardioprotection” will be used to indicate that the agent
educes acute myocardial infarct size or prevents perioper-
tive infarction (in the setting of cardiac surgery) and, as a
esult, reduces the consequences of AMI, including less
ortality, less heart failure (HF), and fewer myocardial-
nfarct-associated ventricular arrhythmias.
From the *Heart Institute, Good Samaritan Hospital, Division of Cardiovascular
edicine, Keck School of Medicine, University of Southern California, Los Angeles,
alifornia; and the †Department of Cardiology, Marshfield Clinic, Marshfield,
isconsin.
Manuscript received January 13, 2004; revised manuscript received March 23,r004, accepted March 31, 2004.ARLY REPERFUSION
he realization that the progression of necrosis could be
nterrupted by early reperfusion and that occlusive thrombi
ere present in the coronary arteries of most ST-segment
levation/Q-wave myocardial infarctions (MIs) ushered in
he era of reperfusion. Reimer et al. (2) performed mechan-
cal coronary occlusions in the circumflex artery of dogs.
he occlusions were transient for different time periods up
o 6 h or were permanent without reperfusion. There was a
rogressive increase in cardiac necrosis, with time beginning
n the subendocardial region and marching toward the
ubepicardial tissue (referred to as the wave-front phenom-
non). If reperfusion was instituted before 3 h of coronary
rtery occlusion, significant salvage within an anatomic risk
one occurred. If reperfusion was instituted beyond 3 to 6 h,
ittle or no salvage occurred compared with a permanent
non-reperfused) coronary occlusion.
Experimentally, early reperfusion has remained the best
trategy so far to limit infarct size (3). Another pivotal study
aved the way for our modern management of AMI.
eWood et al. (4) studied 322 patients presenting with
MI with a coronary angiogram. The study proved beyond
doubt that a thrombus is the usual cause of Q-wave MI,
nd it showed that performing coronary angiography during
he early hours of AMI is safe. Reperfusion therapy with
hrombolytic agents consistently showed a reduction of
yocardial infarct size measured in a variety of fashions:
lectrocardiographic (ECG)—preservation of R waves and
eduction in development of Q waves; enzymes—reduction
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July 21, 2004:276–86 Cardiac Protection During Acute MIn blood levels of creatine kinase MB (CK-MB), lactic
ehydrogenase, beta-hydroxybutyrate, and others (5–9).
hrombolysis reduced mortality (7–9) and improved cardiac
unction (10). In addition, compared with thrombolysis, the
se of angioplasty and stents for early reperfusion results in
etter infarct artery patency, left ventricular (LV) function,
nd lower mortality (11–21). Both thrombolytic therapy and
arly percutaneous coronary intervention became the stan-
ard therapy for patients with MI.
In recent years, studies have attempted to fine-tune the
uccess of early reperfusion with antiplatelet and antithrom-
in agents that should help keep the infarct artery patent.
nquestionably, aspirin has been shown to be a useful
djunct in this regard and is standard therapy for AMI (22).
gents such as low-molecular-weight heparin, rather than
nfractionated heparin, and glycoprotein IIb/IIIa platelet
nhibitors have shown promise in some studies (23,24).
ARDIAC PROTECTION DURING
ARLY PERCUTANEOUS INTERVENTION
trategies that proved successful are those that help to make
he intervention successful in achieving early Thrombolysis
n Myocardial Infarction (TIMI)-III flow. Glycoprotein
Ib/IIIa receptor blockade is an important therapy during
arly coronary stenting. Both eptifibatide and abciximab are
eing utilized with good success in routine clinical practice.
n the Abciximab before Direct angioplasty and stenting in
yocardial Infarction Regarding Acute and Long-term
ollow-up (ADMIRAL) study, 300 AMI patients were
andomized to abciximab or placebo (25). Abciximab pa-
ients had better coronary patency, LV function, and clinical
utcomes. Even in patients who had their intervention
ithin 48 h after the onset of symptoms, abciximab was
linically superior to placebo, with better coronary flow and
nhanced recovery of contractile function (26). In a con-
rolled trial of 400 patients with AMI undergoing stenting,
ntoniucci et al. (27) randomized the patients to abciximab
r control. The composite end point of death, reinfarction,
nd target vessel revascularization was significantly less in
he abciximab group. In addition, infarct size as measured
y technetium-99m (99mTc) sestamibi scintigraphy was
maller in the abciximab group (27). These studies as well as
Abbreviations and Acronyms
AMI  acute myocardial infarction
CABG  coronary artery bypass grafting
CK-MB  creatine kinase-MB
ECG  electrocardiogram/electrocardiographic
GIK  glucose-insulin-potassium
HF  heart failure
LV  left ventricle/ventricular
MI  myocardial infarction
NHE  sodium-hydrogen exchange
RR  risk reductionthers suggest that a IIb/IIIa receptor blocker such as pbciximab should be administered to AMI patients under-
oing stenting (28).
One potential mechanism by which glycoprotein IIb/IIIa
nhibitors may improve outcomes in the setting of early
nterventions is by limiting no-reflow, as recently discussed
29,30). Intracoronary injection of verapamil, adenosine, or
itroprusside may also be used to restore blood flow when
aced with the no-reflow phenomenon in the setting of
ntervention (31). Prophylactic intracoronary adenosine ad-
inistration is effective and is utilized by a significant
umber of interventional cardiologists, particularly in vein
raft intervention. Besides its use in the clinical setting of
o-reflow, adenosine may have other benefits in the setting
f intervention. Leesar et al. (32) randomized 30 patients to
ntracoronary infusion of adenosine 2 mg/min over 10 min
r placebo before percutaneous coronary angioplasty. The
denosine group had less coronary ischemia and enhanced
reconditioning when compared with the control group.
imilar protocols with other agents are being utilized in
atheterization laboratories (33).
ARLY ADJUNCTIVE
HARMACOLOGIC THERAPY IN MI
iven early and successful coronary artery reperfusion, what
lse can be done to further help protect the myocardium
rom various interrelated insults? This is where adjunctive
harmacologic therapy may be important. In this section we
ill refer to early adjunctive therapies as cardioprotective
pproaches used for AMI that show benefit other than
ttaining or maintaining patency of the proximal infarct
rtery. Thus, agents such as thrombolytic agents, aspirin,
lycoprotein IIb/IIIa inhibitors, unfractionated heparin will
ot be considered adjunctive therapies here. Also, angioten-
in converting enzyme inhibitors, known to reduce LV
ilation and remodeling when administered over the long
erm after MI, will not be considered early adjunctive
herapy. Statins clearly play an important role in the
oronary patient and even in those with acute coronary
yndromes. However, primarily this section will focus on
harmacologic agents administered early that are thought to
urther reduce ST-segment elevation myocardial infarct size
r have short-term antiarrhythmic effects on the ischemic/
eperfused myocardium, with the assumption that reperfu-
ion therapy has been successful.
eta blockers. Some (34,35), but not all (36), experimental
tudies performed in large animal models observed that beta
lockade, coupled with reperfusion, reduced myocardial
nfarct size. Beta blockade in the setting of a permanent
oronary artery occlusion failed to reduce infarct size in our
odels (37). Potential mechanisms for benefits in the
eperfusion models included a reduction in heart rate and
ontractility with a decrease in myocardial oxygen demand
hat may have slowed the progression of necrosis into the
eri-infarct tissue, preservation of mitochondrial structures,
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Cardiac Protection During Acute MI July 21, 2004:276–86tabilization of the vasculature, stabilization of cell mem-
ranes, or other as yet unknown mechanisms (34,38,39).
In the pre-reperfusion era Multicenter Investigation of
he Limitation of Infarct Size (MILIS) study (40), propran-
lol started at an average of 8.5 h after onset of symptoms
id not reduce infarct size estimated by measure of serum
K-MB, technetium pyrophosphate myocardial scintigram,
r preservation of R-waves. In retrospect, it is unlikely that
ny agent would reduce infarct size if administered 8 h after
oronary artery occlusion.
However, beta-blockers, when administered early, were
hown to reduce myocardial infarct size even in some studies
one before common use of thrombolytics. Yusuf et al. (41)
tudied 475 patients suspected of having had an AMI
ithin 12 h before randomization. Patients received
ntravenous atenolol and then oral atenolol for 10 days or
ere assigned to a control group. In those patients admitted
ith ECG changes that were definitive for MI at entry,
tenolol reduced cardiac enzyme release by one-third and
reserved R-waves. Atenolol also decreased incidence of
-on-T ventricular ectopic beats and reduced the number of
pisodes of repetitive arrhythmias in the first 24 h. In this
tudy the mean time from chest pain to randomization was
h. The earlier time to therapy may have explained why this
tudy was positive in contrast with the MILIS study. Peter
t al. (42) in a small pre-thrombolytic study showed that
ntravenous propranolol administered within 4 h of onset of
I in patients who demonstrated pathologic Q waves
esulted in 27% lower CK levels compared with control
atients.
The International Collaborative study group (43) assessed
44 patients admitted for AMI within 4 h after onset of
hest pain. Intravenous timolol was administered at a mean
f 3.4 h after symptom onset and was continued for 24 h,
nd then orally thereafter for the duration of the hospital-
zation. Maximal cumulative CK release was reduced by
0%, and there were fewer alterations in QRS vector in
atients receiving timolol versus those receiving placebo.
imolol accelerated the reduction of ST-vector, reduced
hest pain, and reduced the need for analgesia.
Hjalmarson et al. (44) reported the results of a 1,395
atient study in which metoprolol or placebo was started
pon patient arrival with AMI and therapy was continued
or 90 days. Initial therapy was intravenous metoprolol
ollowed by oral therapy. In the placebo group, there was a
ortality rate of 8.9%, while in the metoprolol group,
ortality rate was 5.7% (p  0.03). Infarct size data were
ot provided.
In the large multicenter Metoprolol in Acute Myocardial
nfarction (MIAMI) trial, intravenous metoprolol reduced
yocardial infarct size by enzymatic analysis in patients who
eceived therapy within 7 h of symptoms (45). There was a
5% reduction in mortality by one week in patients who
ere randomized to intravenous atenolol versus placebo in
he First International Study of Infarct Survival (ISIS)-1
tudy (46). Patients received therapy within an average of nh of symptoms of suspected AMI. Also of note, treated
atients had a lower incidence of death due to ventricular
upture when receiving beta blockade. The mortality benefit
f atenolol was maintained for at least the first year of
ollow-up.
In the TIMI-IIB study (47), the effect of immediate
ersus deferred beta-blocker was studied in patients with
MI that were treated with recombinant tissue-type plas-
inogen activator. Patients received either three intrave-
ous injections of 5 mg of metoprolol and then 50 mg twice
day orally for one day and 100 mg twice a day orally
hereafter (immediate therapy), or on day six, 50 mg twice
day orally for one day and then 100 mg twice a day.
While there was no overall difference in mortality be-
ween groups, six-week mortality in low-risk patients was
% and 2.8% in the immediate and deferred beta-blocker
herapy groups, respectively (p  0.007). Reinfarction rates
ere lower at six days and six weeks in the immediate
reatment group versus the delayed treatment group. How-
ver, there was no difference at one year.
Basu et al. (48) showed that early carvedilol was tolerated
n AMI patients and at six months was associated with
ewer cardiac events than placebo.
In the Beta-Blocker Heart Attack trial (also from the
re-thrombolytic era), patients receiving long-term pro-
ranolol treatment, beginning 5 to 21 days after infarction
or 27 months, demonstrated reduced total mortality, car-
iovascular mortality, and sudden death (49). It is likely that
his was an antiarrhythmic effect. Because the beta-blocker
as administered late, this effect could not have involved
nfarct size reduction. Similar observations were made with
ong-term timolol treatment starting seven to 28 days after
MI and continuing for 12 to 33 months. Timolol reduced
ortality, sudden death, and reinfarction rates when com-
ared with placebo (50).
In summary, when administered very early, beta-blockers
ave been suggested to reduce infarct size (even in some
re-reperfusion era studies). Beta-blockers also appear to
educe cardiac arrhythmias and mortality. Early beta-
locker therapy is now a standard part of therapy for AMI
n those patients who can tolerate beta-blockers. Patients
ith severe congestive HF, bronchospasm, bradycardia, or
trioventricular block may not be candidates for beta-
locker therapy.
lucose-insulin-potassium infusion. Experimental stud-
es suggest that glucose-insulin increases glycolytic ATP
ynthesis during hypoxia (51,52). The concept is that insulin
rives glucose into the cells making more glucose available
or anaerobic glycolysis while suppressing levels of free fatty
cid and reducing myocardial free fatty acid uptake.
lucose-insulin-potassium (GIK) infusion also stimulates
otassium re-uptake into cardiac cells, thus decreasing
ctopy. Apstein et al. (53,54) have reviewed the rationale for
IK. Some experimental studies suggested that GIK re-
uced ischemic myocardial damage (55), while others did
ot (56).
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July 21, 2004:276–86 Cardiac Protection During Acute MIIn the pre-thrombolytic era, a number of studies were
onducted to investigate the effect of GIK infusion in the
rst few hours of MI. Most did not have enough statistical
ower to reach a definitive conclusion. A meta-analysis by
ath-Ordoubadi and Beatt (57) suggested that GIK has a
ortality benefit in the setting of acute infarction.
In the thrombolytic era, Diaz et al. (58) randomized 407
atients with suspected AMI to GIK or a comparable
lacebo. Some of those patients (38%) did not receive a
eperfusion strategy. There was a trend toward a mortality
enefit in the overall study population who received GIK. In
atients who had a reperfusion strategy, there was a statis-
ically significant mortality benefit (risk reduction [RR] 
.34; 95% confidence interval [CI] 0.5 to 0.78; p  0.008),
nd these patients showed a non-significant trend toward
ess severe congestive HF and ventricular fibrillation. The
enefit was more marked in patients who started treatment
oon after the onset of symptoms, a trend that is consistent
n all proven therapies for MI. The incidence of electrome-
hanical dissociation was lower in the GIK group versus
ontrols (1.5% vs. 5.8%; p  0.016). Of note in this study,
he mortality rate in the control group was 11.5%, which is
ore than double the current mortality rate for AMI.
Malmberg et al. (59) randomized 306 AMI patients with
iabetes mellitus to glucose-insulin infusion or to conven-
ional therapy. Diabetic patients who received the active
herapy had a significant reduction in mortality at one year
fter the onset of the infarction (18.6% vs. 26.1%; p 0.03).
t 3.4 years, the benefit in mortality persisted (33% vs. 44%;
 0.01).
van der Horst et al. (60) randomized 940 AMI patients
ligible for percutaneous transluminal coronary angioplasty
o continuous GIK infusion versus no infusion beginning 15
o 20 min after hospital admission. The primary end point
f the study was 30-day mortality. At 30 days, 23 of 476
atients (4.8%) died in the GIK group versus 27 of 476
5.8%) in the placebo group (pNS). In patients (n 856)
ithout HF, GIK significantly reduced mortality (from
.2% in controls to 1.2% in the GIK group; RR  0.28;
5% CI 0.1 to 0.75). In contrast, in patients with signs of
F (n  84), 30-day mortality was 36% in the GIK group
ersus 26.5% in the controls (RR  1.44; 95% CI 0.65 to
.22). Infarct size parameters were not reported.
The last word on GIK has yet to be written. There clearly
s a suggestion that this therapy may reduce mortality in
ertain subgroups of patients, but it is not at all clear that
his is related to an infarct size-reducing effect. There is a
eed for a large clinical infarct size study using this agent
ombined with reperfusion.
odium-hydrogen exchange inhibitors. A number of
tudies with the sodium-hydrogen exchange (NHE) inhib-
tor agent cariporide were positive in experimental models
61,62). In our studies, 30 min of coronary artery occlusion
nd 3 h of reperfusion cariporide reduced infarct size by 55%
n a rabbit model. The mechanisms by which cariporide and
ther NHE work involve a decrease in the influx of sodium (nto ischemic cells. This ultimately inhibits the exchange of
odium for calcium. Calcium overload of the myocardial cell
s thought to lead to major disruption of metabolism and
rchitectural disruption, including the formation of contrac-
ion band-type necrosis and precipitation of calcium phos-
hate granules within the mitochondria.
Rupprecht et al. (63) gave 40 mg cariporide or placebo
ntravenously over 10 min followed by percutaneous trans-
uminal coronary angioplasty in AMI patients. End-systolic
olume increased over three weeks in the placebo group (80
o 97 ml) but decreased in the cariporide group (77 to 69 ml;
 0.048). Ejection fraction was unchanged over three
eeks in the placebo group (40% to 40%) but increased in
he cariporide group (44% to 50%; p  0.05). There was
lso improvement in regional wall motion abnormality with
ariporide. Cariporide reduced myocardial infarct size, as
he area under the curve for CK-MB was lower in the
ariporide group versus the placebo group (p  0.047).
Although the Guard During Ischemia Against Necrosis
GUARDIAN) trial (64) was not primarily an acute
-wave MI trial, it did investigate the effects of different
oses of cariporide versus placebo in patients with various
schemic syndromes (unstable angina, non–ST-elevation
I, and high-risk percutaneous or surgical revasculariza-
ion). The primary end point of all-cause mortality or MI at
6 days did not differ between groups. The highest dose
120 mg) showed a non-significant 10% reduction in the
rimary outcome. The 20- and 80-mg doses showed no
rend. At 120 mg, the benefit was limited to patients
ndergoing coronary artery bypass grafting (CABG) (RR,
5%; 95% CI, 3.1 to 41.5; p  0.03) and was maintained at
ix months. Overall, CK-MB scores were similar among the
our groups. The ratio of peak CK-MB elevation to the
pper limit of normal tended to be lower with increasing
oses of cariporide in surgical patients. The rate of Q-wave
I was decreased 32% across all entry diagnoses (p 
.005). The rate of non–Q-wave MI was decreased in
ABG patients only. Thus, in patients undergoing CABG,
ariporide very effectively reduced the incidence of periop-
rative Q- and non–Q-wave myocardial infarcts, perhaps
nderscoring the importance of early therapy in an ischemic
vent. This will be discussed in more detail in the section of
rotection during CABG.
Eniporide, another inhibitor of the NHE, was investi-
ated in patients with AMI (65). A total of 1,411 patients
ere randomized to eniporide or placebo. There was no
ifference in the infarct size between the groups. Moreover,
here was a trend toward excess death and stroke in patients
eceiving eniporide. Thus, while NHE inhibitors appeared
eneficial in some studies, not all were positive, and there
ere some unpredictable adverse events when administered
n a recent cardiac surgical study (see the following text).
learly additional research on these agents is needed.
denosine. Adenosine or adenosine receptor agonists have
een shown to reduce AMI in some experimental studies
66,67). Adenosine can induce coronary artery vasodilation,
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Cardiac Protection During Acute MI July 21, 2004:276–86everse coronary spasm, and replenish high-energy phos-
hates. It can reduce afterload and heart rate, thus decreas-
ng myocardial oxygen demand. In addition, it has anti-
latelet and anti-neutrophil effects that may help prevent
o-reflow in the clinical setting. Adenosine receptor stim-
lation also is thought to be a key component in ischemic
reconditioning (66). As mentioned, when adenosine was
dministered to patients before angioplasty, there was less
hest pain and ST-segment change on the ECG. Prelimi-
ary studies with intracoronary adenosine showed some
romise during early intervention for MI (68). In a random-
zed study of 54 AMI patients, adenosine resulted in
mproved ventricular function and less cardiac enzyme
elease (69). Adenosine agonist, however, in the AmP579
elivery for Myocardial Infarction REduction (ADMIRE)
tudy did not result in a significant effect on infarct size. In
he contemporary interventional practice, intracoronary
denosine use is limited to treatment of no-reflow—and at
much smaller dose than the one utilized in the published
tudies (70).
In a pilot study, Mahaffey et al. (71) examined the effect
f 70 g/kg/min adenosine infusion for 3 h in the setting of
MI. A total of 236 patients were randomized to adenosine
r placebo in an open-label study. The adenosine group had
significant reduction in the size of MI assessed by
echnetium-99m sestamibi single photon emission com-
uted tomography. No clear conclusion was reached regard-
ng clinical event rate. Quintana et al. (72) reported that
denosine reduced cardiac complications in patients with
cute anterior wall MI. In that study, 680 patients with
MI were randomized to intravenous adenosine infusion or
lacebo. Although there was no mortality or hemodynamic
enefit in the overall cohort, those with anterior AMI had
statistically better survival with adenosine. These studies
aved the way for a more definitive study, the Acute
yocardial Infarction Study of Adenosine (AMISTAD) II
73). In this study, 2,084 patients with AMI were random-
zed to a 3-h infusion of adenosine or placebo within 15 min
f reperfusion. Adenosine therapy was associated with
maller infarct sizes and a non-significant trend toward less
ncidence of congestive HF or death. Median myocardial
nfarct size measured utilizing technetium-99m sestamibi
ingle photon emission computed tomography imaging at
20 to 216 h after randomization was 27% in the placebo
roup, 23% in the 50-g/kg/min adenosine group, and 11%
p 0.05 vs. placebo) in the 70-g/kg/min group. Whether
denosine had a direct effect of cardioprotection on the
eart muscle cells or had a beneficial effect by its known
ntiplatelet effect (antiplatelet aggregation), and thus by
eeping the infarct artery or the microvasculature open, is
ot clear. Although adenosine and adenosine agonists are
nown to have preconditioning-like effects, it is unlikely
hat such an effect was the mechanism in the AMISTAD
tudies, because the drug was not administered until after
oronary occlusion, usually later in the occlusion phase. malcium channel blockers. Since their discovery, calcium
hannel blockers were investigated in a variety of cardiovas-
ular diseases, including chronic angina, variant angina,
ypertensive heart disease, and other conditions, with clear
uccess. One condition, however, in which this group of
rugs demonstrated no clear benefit was AMI, despite the
act that calcium channel blockers were shown to limit
yocardial infarct size in some experimental models (74).
owever, even in these experimental models, the calcium
hannel blockers had to be on board during the period of
schemia (that is, not just reperfusion) to demonstrate a
enefit (75). Goldbourt et al. (76) administered nifedipine
n a dose up to 60 mg or placebo to 1,006 patients with
MI. There was increased mortality in the nifedipine group
nd no clinical benefit noted. This may be related to a
ecrease in perfusion pressure, thus decreasing collateral
oronary blood flow among other possibilities. Calcium
hannel blockers are not routinely recommended in the
etting of AMI. Diltiazem and verapamil may be used only
f there is another clear clinical indication (such as hyper-
ension or rapid arrhythmia) and in the absence of conges-
ive HF and heart block. Amlodipine, felodipine, and
isoldipine may be safer agents to administer for ongoing
ypertension or angina in the setting of HF. They, unlike
iltiazem, verapamil, and nifedipine, do not appear to
xacerbate HF. Short-acting calcium channel blockers
hould not be used, as they may induce reflex tachycardia
nd hypotension.
ATP channel openers. Many investigators believe that a
ajor mechanism for the beneficial effects of ischemic
reconditioning is the opening of KATP channels (77),
ither on the cardiac sarcolemmal membrane or mitochon-
rial membranes. Numerous experimental animal studies
ave shown that KATP channel openers such as nicorandil,
emakalin (78), and diazoxide (a mitochondrial KATP chan-
el opener) have preconditioning mimetic properties, while
ATP channel blockers (glibenclamide) (79) can actually
lock ischemic preconditioning. There are several presumed
echanisms that have been suggested. Initially, it was
ypothesized that by opening KATP channels, the cell would
ecome bathed in K, resulting in a decrease in action
otential duration, hence, a localized cardioplegic effect
77). A newer theory postulates that KATP channel blockade
f the mitochondrial membrane is crucial for preserving
itochondrial respiration and cellular metabolism (80).
here is a scarcity of clinical data that have examined the
ffect of KATP channels in humans in the midst of an AMI.
icorandil is a KATP channel opener that also has some
itrate-like activity. It is approved in some countries for the
reatment of angina. The Impact Of Nicorandil in Angina
IONA) trial assessed the potential cardioprotective effects
f nicorandil in patients with stable angina (81). Patients (n
5,126 with stable angina) receiving optimal medical
herapy were randomized to nicorandil or placebo and
ollowed up for a mean of 1.6 years. Coronary heart disease
ortality was 2.3% in the nicorandil group versus 2.9% in
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July 21, 2004:276–86 Cardiac Protection During Acute MIhe placebo group. The primary combined end point of
oronary heart disease mortality, MI, or hospital admission
or cardiac chest pain occurred in 13.1% in the nicorandil
roup versus 15.5% in the placebo group (hazard ratio, 0.83;
5% CI, 0.72 to 0.97; p  0.014). Coronary heart disease
ortality or MI occurred in 4.2% versus 5.2% in the
icorandil versus placebo group (p  0.068). The secondary
nd point of coronary heart disease mortality, MI, or
nstable angina was 6.1% in the nicorandil group versus
.6% in the placebo group (p  0.028). Nonfatal MI
ccurred in 2.1% in the nicorandil group versus 2.8% in the
lacebo group. Thus, although nicorandil showed benefits
n certain combined end points, at least a portion of this
enefit may have been secondary to its antianginal effect.
uture studies in which infarct size is measured using KATP
hannel openers are indicated, especially given the positive
ffect reported with such agents in experimental trials.
egative and controversial modalities. Inhibition of leu-
ocyte adhesion was thought to be beneficial in reducing
nfarct size. Two separate clinical trials utilizing antibodies
o leukocyte adhesion molecules have failed to show any
enefit (82,83). Despite promising results in laboratory
nimals, studies of oxygen radical scavenging drugs such as
rimetazidine (84) and superoxide dismutase (85) have been
egative in humans. Data on early administration of mag-
esium in MI have been mixed. In one older study (86)
ntravenous magnesium administered early reduced 28-day
ortality from 10.3% in the placebo group to 7.8% in the
agnesium group (p  0.04). Magnesium also reduced
linical left ventricular HF. In a more recent trial, there was
o difference in mortality, HF, or incidence of ventricular
brillation in patients who received magnesium versus
ontrol (87). There are a lack of data regarding its effect on
yocardial infarct size in man. Two recent reports showed
hat complement antibodies administered to patients receiv-
ng either thrombolytics (88) or angioplasty (89) had no
ffect on myocardial infarct size. However the anti-C5
omplement agent did reduce mortality at 90 days (1.8% vs.
.9%; p  0.014) in patients treated with primary percuta-
eous intervention, suggesting a benefit unrelated to infarct
able 1. No Consistent Benefits as Early Adjunctive Therapy in
linical Trials
nhibitors of neutrophil adhesion
alcium channel blockers
SOD (superoxide dismutase)
eothrex (110)
rimetazidine (antioxidant)
olsidomine (nitric oxide donor) (111)
luosol (112)
yaluronidase (pre-thrombolytic study) (113)
orticosteroids
eta blockers (given late and without reperfusion)
omplement inhibition (no effect on infarct size; reduced mortality in
one study)ize (89). Table 1 lists these and other agents that, in teneral, have not shown reductions in myocardial infarct
ize or other reproducible benefits in humans.
Hypothermia is a useful technique in reducing or delaying
ecrosis of cells. In laboratory animals, it was shown to
educe myocardial infarct size (90). However, in order to
educe infarct size, hypothermia had to be on board during
he phase of ischemia. Hypothermia only at the time of
eperfusion was unsuccessful (91). A recent preliminary
eport by the COOL-MI trial (TCT Meeting, Washing-
on, DC, September 2003) showed no overall reduction in
MI size in patients undergoing cooling via a heat exchange
atheter placed into the inferior vena cava before angio-
lasty. However, in patients with anterior wall MIs, it was
bserved that patients cooled to temperatures less than 35°C
t the time of reperfusion had significantly smaller infarcts
9.3% of the LV) versus controls (18.2%; p  0.05). One
roblem noted by the investigators was that core tempera-
ures were not cooled quickly enough before angioplasty,
hile angioplasty was accomplished rather quickly.
In reviewing the literature on reduction of AMI, it is clear
hat many positive studies in the experimental animal
iterature have failed to translate to benefit in clinical trials.
hy? There are several potential reasons. One is that, in
early all animal studies, the MI is produced by mechani-
ally occluding an otherwise normal proximal coronary
rtery. Atherosclerosis is not present, and atherosclerotic
ebris, thrombus, and emboli that may occur in the setting
f early percutaneous intervention are less of an issue. In
ddition, the non-infarct-related coronary arteries are free
f disease in most of these models. Perhaps in humans
here platelets and neutrophils are more likely to adhere to
amaged endothelial, a multipronged approach is needed.
n example might be that antibodies to CD18 adhesion
olecules were found to reduce infarct size in some exper-
mental models, but failed to reduce infarct size in humans
82,83). Perhaps if CD18 inhibitors had been coupled with
lycoprotein IIb/IIIa inhibitors, preventing neutrophil ad-
esion as well as platelet aggregates, a benefit might have
een observed. Another issue is that clinical trials have often
een based on experimental observations from only one or
wo experimental laboratories. Sometimes the laboratories
ave a vested interest in the compound. Often drugs are not
ested in a randomized or blinded fashion. Sometimes bias,
ubconscious or otherwise, creeps in. Fellows may fear that
negative result will adversely affect their career or upset the
enior investigator, who is convinced the compound works.
consortium of experimental laboratories that use similar
echniques and that can test compounds in a multicenter
pproach (much like most clinical trials are conducted) may
uccessfully be used to screen compounds. We recently had
he opportunity to participate with two other laboratories in
his multicenter approach. All three laboratories used a
abbit model and similar basic techniques for assessing risk
one and myocardial infarct size. In addition, all three
aboratories were blinded to drug therapy, and administra-
ion of drug versus placebo was randomized. All three
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Cardiac Protection During Acute MI July 21, 2004:276–86aboratories found similar results (92). Although the results
f our study did not show a positive effect of the compound,
e probably saved the company sponsoring the study
illions of dollars had they proceeded with a clinical trial
ased on positive results from only a single laboratory. In
he authors’ opinion, there is a need for a national or
nternational consortium of basic science laboratories that
an reliably test the effect of compounds on myocardial
nfarct size in an unbiased, randomized, and blinded fash-
on. These types of translational experimental studies could
e carried out in a parallel fashion to the large clinical
ulticenter studies now so common in the cardiovascular
iterature.
ARDIAC PROTECTION DURING SURGERY
s early as the 1960s, the perioperative complication of
icroinfarctions was recognized as a problem that could
ead to the syndrome of low cardiac output and even death
93). Perioperative MI is one of the most important adverse
vents occurring during bypass surgery. The incidence varies
idely in various studies because there is no uniform
efinition and ranges between 3% and 30% (94). In a review
f 499 consecutive CABG patients at Brigham and Wom-
n’s Hospital in 1992 to 1993, 5% of patients were reported
o have had perioperative MIs, and 2% had probable
erioperative infarctions. The definitions included total
eak creatine kinase 700U/l, a CK-MB of more than 30
g/ml with definite pathologic Q-wave, or new regional
all motion abnormalities. Multivariant analysis showed
hat emergency surgery, aortic cross-clamp time more than
00 min, recent MI within one week, previous revascular-
zation, and diabetes were associated with increased inci-
ence.
In another review by Mayo Clinic investigators (95),
ther factors that affected the incidence of perioperative MI
ncluded collateral flow, duration of aortic cross-clamping,
he extent of coronary artery disease, need for endarterec-
omy, and adequacy of myocardial protection. In the last few
ears, off-pump CABG has emerged as a viable alternative
o traditional surgery. Even though the surgery is done on a
eating heart, perioperative MI in the non-bypassed regions
as been reported. Recent comparative studies showed that
ff-pump cases are associated with fewer short-term com-
lications, yet in long-term follow-up, graft patency was
able 2. Proven Benefit in Acute Myocardial Infarction
arly reperfusion—attain and maintain coronary patency
Stents  percutaneous transluminal coronary angioplasty
 thrombolysis
gents to help maintain patency:
Aspirin
Low-molecular-weight heparin
Glycoprotein IIb/IIIa inhibitor with percutaneous coronary
intervention
ntravenous beta-blocker (given early)ower. Perioperative myocardial injury is associated with
levated early and late mortality (96).
Perioperative infarction also may be related to the in-
rease in myocardial oxygen demand that occurs during
nesthesia induction, during the period of cardiopulmonary
ypass itself, or in the early postoperative recovery period
97). The most vulnerable period for development of myo-
ardial necrosis is during the surgery itself. The ischemic
njury during cardiopulmonary bypass is not necessarily
elated solely to the presence or severity of coronary artery
isease. Hultgren et al. (98) studied 126 patients undergo-
ng valve replacement in which there was no evidence of
oronary artery disease. Significant creatine phosphokinase
elease occurred in 40% of patients. Despite the current
echniques utilized to protect the heart during cardiac
urgery, cardiac enzyme release still occurs in over half the
atients undergoing CABG (99). Mortality appears to be
elated to the extent of enzyme release (100). The following
iscussion reviews some of the new techniques and drugs
hat have been investigated for myocardial protection during
ABG.
schemic preconditioning. It is thought that because isch-
mic preconditioning is protective during various ischemic
nsults, it may play a role during cardiac surgery (101).
hosh and Galinanes (102) investigated the effect of
reconditioning during cardiopulmonary bypass and in
ff-pump bypass. In the former, ischemic preconditioning
as done by brief aortic cross-clamping for 5 min followed
y 5 min of reperfusion before the intervention. There was
o benefit noted. In off-pump bypass, the individual coro-
ary artery was clamped for 5 min followed by 5 min of
eperfusion before the coronary surgery, and patients were
ompared with a control group. The ischemic precondition-
ng group had less troponin T enzyme release 48 h after
urgery. Many surgeons performing off-pump bypass now
tilize this technique.
harmacologic intervention. A variety of medications had
een investigated either by direct administration in the
ardioplegic solution or by systematic administration just
able 3. Possible Benefit as Early Adjunctive Therapy
lucose-insulin-potasium or glucose-insulin
denosine (anterior wall myocardial infarctions)
ariporide
ypothermia (in anterior wall myocardial infarctions with temperature
35°C)
able 4. Agents Administered Over the Long Term After
yocardial Infarction That Have Benefit by Decreasing Left
entricular Remodeling or Improving Outcome by Other
eans
ngiotensin converting enzyme inhibitors
plerenone (aldosterone receptor antagonist)
ngiotensin receptor blockers
tatins
-3 polyunsaturated acids
ong-term beta-blockade
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July 21, 2004:276–86 Cardiac Protection During Acute MIefore initiation of cardiopulmonary bypass. Some studies
ith adenosine (103) and esmolol (104) did not have a
ignificant clinical benefit despite the initial enthusiasm that
as derived from animal studies (105). One study, however,
rovided some hope with high-dose adenosine added to
old blood cardioplegia. Mentzer et al. (106) randomized
53 patients into high-dose adenosine, low-dose adenosine,
r no adenosine. There was a trend towards a lower
ncidence of perioperative MI and less need for hemody-
amic support in the high-dose adenosine group. A large-
cale study utilizing the high dose will settle this issue. A
mall randomized study utilizing nifedipine cardioplegia in
24-patient study showed some benefit in decreasing
ardiac necrosis and arrhythmias after cardiopulmonary
ypass (107). This study was neither confirmed nor had any
mpact on today’s clinical practice.
The most recent emphasis in clinical investigation is the
rugs that affect NHE activation during myocardial isch-
mia and reperfusion. Cardiac ischemia leads to intracellular
cidosis. The NHE is activated with an increase in the
a-Ca2 exchange with significant intracellular hypercal-
emia that may contribute to myocyte necrosis. Cariporide,
n NHE inhibitor, may have the potential of interrupting
his cycle with a decrease in cardiac necrosis during cardio-
ulmonary bypass. Boyce et al. (108) reported the effect of
varying dose of cariporide infusion 1 h before surgery at
oading doses ranging from 20 to 120 mg. Only the dose of
20 mg had a significant reduction in all-cause mortality
nd MIs. The clinical benefit was maintained for about six
onths. A more definitive study randomized 5,761 patients
o cariporide (180 mg/h preoperatively followed by 40 mg/h
nfusion for 24 h and 20 mg/h for an additional 24 h) or
lacebo (109). Although patients in the cariporide group
ad significantly fewer perioperative MIs, there was a
urprisingly significant increase in mortality, strokes, and
enal failure. The increase in ischemic strokes continued to
e noted six months after randomization. This study keeps
he concept of cardioprotection by inhibiting NHE system
live, yet it raises a real question about the safety of this
articular drug or its dose. The quest for cardioprotection
uring cardiopulmonary bypass, however, should continue,
articularly because patients who are having this procedure
ow are older and a higher risk population who may require
onger cross-clamp time.
ONCLUSIONS
any pharmacologic agents and strategies have been ad-
inistered for cardiac protection during AMI. Tables 1 to 4
eview those agents that failed to show short-term benefit in
arge clinical trials (110–113), those strategies that have
een shown to benefit AMI in the short term, those agents
hat may possibly benefit AMI in the short term, and those
gents that benefit the heart when administered over the
ong term. It is clear that the best cardioprotection in the
etting of AMI is opening the coronary occlusion as early asossible and a restoration of TIMI-III coronary flow. Early
oronary intervention is superior when it can be done in a
imely manner by an experienced center. Our resources
hould be focused on decreasing the period between onset of
ymptoms and early intervention. Efforts should include
etter public awareness of the symptoms of infarction and
pecific hospital initiatives to shorten the time from arriving
t the emergency department to initiation of thrombolytic
herapy, or inflation of the first coronary balloon, or place-
ent of stent. Regarding active adjunctive therapy, intrave-
ous beta blockers (where tolerated) clearly show benefit.
UTURE DIRECTIONS
dditional clinical trials are needed to study those classes of
harmacologic agents that show promise as adjunctive
herapies. Studies investigating the effect of KATP channel
peners, adenosine, adenosine receptor agonists, GIK, and
ewer NHE inhibitors are needed. Early hypothermia
hows promise if cooling can be achieved more rapidly, that
s, before coronary artery reperfusion.
During early coronary intervention, intravenous IIb/IIIa
dministration and intracoronary verapamil or adenosine
nfusion provide significant cardiac protection from no-
eflow during the procedure. Temporary arterial occlusion
rovides protection during off-pump CABG. Sodium-
ydrogen exchange and various cardioplegic solutions are
nder active investigation to achieve the best cardioprotec-
ion strategy during on-pump bypass surgery.
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